(NP (NP (NN Inhibition)) (PP (IN of) (NP (NN HIV-1) (NN latency) (NN reactivation))) (PP (IN by) (NP-COOD (NP (NP (NN dehydroepiandrosterone)) (PRN (-LRB- -LRB-) (NP (NN DHEA)) (-RRB- -RRB-))) (CC and) (NP (NP (DT an) (NN analog)) (PP (IN of) (NP (NN DHEA)))))) (. .))
(S (NP-SBJ (NP (DT The) (JJ initial) (NN infection)) (PP (IN with) (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJS most) (NNS individuals)))) (ADVP-TMP (RB usually)) (VP (VBZ results) (PP (IN in) (NP (NP (DT the) (NN establishment)) (PP (IN of) (NP (DT a) (ADJP-COOD (ADJP (JJ latent)) (CC or) (ADJP (JJ chronic))) (NN infection))) (PP-TMP (IN before) (NP (NP (JJ eventual) (NN progression)) (PP (IN toward) (NP (VBN acquired) (NN immunodeficiency) (NN syndrome)))))))) (. .))
(S (NP-SBJ (NN HIV-1)) (VP (MD can) (ADVP (RB also)) (VP (VB establish) (NP (DT a) (ADJP-COOD (ADJP (JJ latent)) (CC or) (ADJP (JJ persistent))) (NN infection)) (PP (IN in) (NP (NP (DT some) (NN T) (NN cell) (NNS lines)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ (-NONE- *T*-1)) (VP (VBP show) (NP (JJ minimal) (JJ constitutive) (NN virus) (NN expression))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP-SBJ-2 (NP (NN activation)) (PP (IN of) (NP (DT the) (NN T) (NN cell) (NNS lines))) (VP (VBG leading) (PP (TO to) (NP (VBN enhanced) (NN HIV-1) (NN replication))))) (VP (MD can) (VP (VB be) (VP (VBN induced) (NP (-NONE- *-2)) (PP (IN by) (NP-LGS (NP-COOD (NP (NNS antigens)) (, ,) (NP (NNS mitogens)) (, ,) (CC and) (NP (NNS cytokines))) (PRN (-LRB- -LRB-) (NP-COOD (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LCB-) (NP (NN TNF-alpha)) (-RRB- -RCB-))) (, ,) (NP (NN interleukin) (CD 1)) (, ,) (CC and) (NP (NN interleukin-2))) (-RRB- -RRB-))))))) (. .))
(S (NP-SBJ (NP (JJ Various) (NN gene) (NNS products)) (PP (IN from) (NP (NP (JJ other) (NNS viruses)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN HTLV-1)) (, ,) (NP (NN HSV)) (, ,) (NP (NN EBV)) (, ,) (NP (NN CMV)) (, ,) (NP (NN HBV)) (, ,) (CC and) (NP (NN HHV-6))) (-RRB- -RRB-))))) (VP (MD can) (ADVP (RB also)) (VP (VB enhance) (NP (NN HIV-1) (ADJP (JJ long) (JJ terminal) (NN repeat) (-LRB- -LRB-) (NN LTR) (-RRB- -RRB-) (JJ -driven)) (NN reporter) (NN gene) (NN activity)))) (. .))
(S (PP (IN On) (DT the) (NN basis) (IN of) (NP (DT these) (NNS observations))) (, ,) (NP-SBJ (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN proposed) (SBAR (IN that) (S (NP-SBJ (NP (NN reactivation)) (PP (IN of) (NP (NP (JJ latent) (NN HIV-1)) (VP (VBN harbored) (NP (-NONE- *)) (PP (IN in) (NP (ADJP (RB chronically) (JJ infected)) (NP-COOD (NP (NN T) (NNS lymphocytes)) (, ,) (NP (NNS monocytes)) (, ,) (CC or) (NP (NNS macrophages))))))))) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN AIDS))))))))))) (. .))
(S (ADVP-TMP (RB So) (RB far)) (, ,) (NP-SBJ (EX there)) (VP (VBP are) (NP-PRD (NP (DT no) (NP-COOD (NP (NNS drugs)) (CC or) (NP (NN therapy)))) (ADJP (JJ available)) (SBAR (WHNP-3 (WDT that)) (S (NP-SBJ (-NONE- *T*-3)) (VP (MD can) (VP (VB provide) (NP (NP (NN protection)) (PP (IN against) (NP (NN HIV-1) (NN latency) (NN reactivation)))))))))) (. .))
(S (NP-SBJ (NP (NN ACH-2)) (, ,) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (NP (DT a) (JJ human) (NN T) (NN cell) (NN line)) (PRN (-LRB- -LRB-) (NP (NN CEM)) (-RRB- -RRB-))))) (, ,)) (VP (VBZ is) (ADJP-PRD (RB chronically) (VBN infected) (PP (IN with) (NN HIV-1))) (, ,) (PP (IN with) (NP (NP (JJ low) (NNS levels)) (PP (IN of) (NP (JJ constitutive) (NN virus) (NN expression)))))) (. .))
(S (NP-SBJ-4 (NN ACH-2)) (VP (MD can) (VP (VB be) (VP (VBN converted) (NP (-NONE- *-4)) (PP (TO to) (NP-COOD (NP (NP (JJ productive) (NN infection)) (PP (IN by) (NP (NP (NN stimulation)) (PP (IN of) (NP (DT the) (NNS cells))) (PP (IN with) (NP-COOD (NP (NP (NN 12-O-tetradecanoylphorbol-13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))) (, ,) (NP (NN mitogen)) (CC or) (NP (NP (NNS cytokines)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-)))))))) (, ,) (CC or) (NP (NP (NN infection)) (PP (IN with) (NP (NN HSV))))))))) (. .))
(S (ADVP (RB Therefore)) (NP-SBJ (DT the) (NN ACH-2) (NN cell) (NN line)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ good) (NN candidate)) (PP (IN for) (S (NP-SBJ (-NONE- *)) (VP (VBG studying) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNS drugs))) (PP (IN on) (NP (NN HIV-1) (NN activation))))))))) (. .))
(S (ADVP-TMP (RB Previously)) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN reported) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN DHEA)) (CC and) (NP (NP (JJ synthetic) (NNS analogs)) (PP (IN of) (NP (NN DHEA))))) (VP (MD can) (VP (VB be) (NP-PRD (NP (JJ modest) (NNS inhibitors)) (PP (IN of) (NP (NN HIV-1) (NN IIIB) (NN replication)))) (PP (IN in) (NP (JJ phytohemagglutinin-stimulated) (JJ peripheral) (NN blood) (NN lymphocyte) (NNS cultures))))))))) (. .))
(S (-LRB- -LRB-) (NP-SBJ-5 (NN ABSTRACT)) (VP (VBN TRUNCATED) (NP (-NONE- *-5)) (PP (IN AT) (NP (CD 250) (NNS WORDS)))) (-RRB- -RRB-))
